Combination therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two experimental drugs (AK104 and AK112) combined with an oral tablet (TT-00420) for people with advanced hepatocellular carcinoma (a type of liver cancer) who have not had previous systemic treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced liver cancer (hepatocellular carcinoma) that cannot be treated with local therapies like surgery or ablation.
- You must have at least one measurable tumor (by imaging) that can be tracked over time.
- Your liver function must be well enough (Child-Pugh score of 7 or less) and you should be in good daily health (ECOG 0 or 1).
- If you have hepatitis B or C, it must be well controlled with medication.
- You must not have had any prior systemic cancer treatments for liver cancer (for specific groups).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
This trial tests a new drug called TPST-1120 combined with two standard treatments (atezolizumab and bevacizumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination works better than the standard approach alone.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This trial tests a combination of three treatments—a targeted artery procedure, a growth-blocking drug (apatinib), and an immune-boosting drug (camrelizumab)—for people with advanced liver cancer who cannot or do not want surgery. The goal is to shrink tumors and improve survival.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.